Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Takeda’s Daxas Fails to Win U.K. Cost Agency’s Backing

Takeda Pharmaceutical Co.’s Daxas lung drug failed to win the backing of the U.K.’s health-cost agency in final guidance on the treatment of severe chronic obstructive pulmonary disease.

The drug, also known as roflumilast, is most likely to be used in addition to triple therapy, but there wasn’t direct clinical evidence to the product’s use in that way, the National Institute for Health and Clinical Excellence said in an e-mailed statement. The agency repeated its recommendation to conduct a trial of Daxas in combination with other commonly used treatments to prove the drug offers an advantage.

Merck & Co. last month ended its agreement with Japan’s Takeda to promote the drug in certain European countries and Canada.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.